查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1881995

羥孕酮己酸酯注射液市場報告：趨勢、預測及競爭分析（至2031年）

Hydroxyprogesterone Caproate Injection Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

受早產預防和荷爾蒙補充療法市場機會的推動，全球己酸羥孕酮注射市場預計將呈現成長態勢。預計2025年至2031年，全球己酸羥孕酮注射市場將以6.2%的複合年成長率成長。該市場的主要促進因素包括早產病例數的增加、孕產婦保健療法需求的成長以及對產前護理解決方案日益成長的關注。

  • 根據 Lucintel 的預測，多劑量管瓶在預測期內有望呈現更高的成長率。
  • 從應用領域來看，預防早產領域預計將呈現更高的成長率。
  • 從地區來看，預計北美在預測期內將出現最高的成長率。

羥孕酮己酸酯注射劑市場的新趨勢

由於對其臨床療效的重新評估，羥孕酮己酸酯注射液市場目前正經歷著巨大的不確定性和萎縮期。新興趨勢並非著眼於成長，而是致力於徹底擺脫對該藥物的依賴，這凸顯了人們對預防早產的替代和更有效干預措施的渴望。

  • 轉向替代孕激素：最顯著的趨勢是從羥孕酮己酸酯轉向替代孕激素，尤其是天然黃體素。鑑於近期臨床療效和良好安全性方面的更多證據，醫療保健提供者擴大將陰道或口服黃體素作為替代方案，這正在改變市場格局。
  • 對黃體素研究的關注度提高：對己酸羥孕酮的監管措施推動了對孕酮在懷孕中作用的研究不斷深入。科學家目前致力於闡明孕酮的作用機轉和最佳給藥方法，以期找到真正有效且安全的早產治療方法。
  • 個人化醫療的進展：預防早產的一個新興趨勢是轉型為個人化醫療。與採用「一刀切」的方法不同，個人化醫療越來越重視識別個別患者的風險因素，例如子宮頸長度，從而能夠進行更有針對性、更有效的干涉，而不僅僅依賴單一藥物。
  • 臨床試驗資料的重新評估：一個重要的趨勢是對以往臨床試驗資料的重新評估。羥孕酮己酸酯療效試驗的失敗凸顯了產科領域需要進行更嚴謹、設計更完善的研究，這也提高了未來藥物核准和醫學證據的標準。
  • 更重視非藥物療法：羥孕酮己酸酯的挑戰促使人們重新關注非藥物療法，包括生活方式調整、改善孕產婦營養和綜合護理模式。這種轉變強調綜合辦法關注孕產婦健康和福祉。

羥孕酮己酸酯市場的新趨勢是萎縮而非成長。監管措施和科學研究結果凸顯了其無效性和潛在風險，正在重塑市場格局，促使人們轉向更安全、更有效的替代方案，並開啟了孕產婦健康研究的新時代。

羥孕酮己酸酯注射劑市場的最新趨勢

羥孕酮己酸酯注射劑市場近期經歷了顯著變化，主要原因是監管機構採取的行動對該藥物的長期使用提出了質疑。這些變化導致該藥物從主要市場撤出，並迫使人們重新評估預防早產的治療策略。

  • 美國FDA撤銷Makena的核准：美國食品藥物管理局（FDA）做出了一項具有里程碑意義的決定，並將於2023年撤銷對Makena（商品名：己酸羥孕酮注射）的核准。先前，驗證性試驗未能證明其臨床療效，因此該藥物實際上已從美國市場撤出。
  • 歐洲藥品管理局 (EMA)建議暫停該藥物在歐盟的上市核准：與此同時，歐洲藥品管理局 (EMA)建議暫停該藥物在歐盟的上市許可，理由是該藥物在預防早產方面療效不佳，並且可能（未經證實但令人擔憂）會增加後代患癌的風險。此舉與美國食品藥物管理局 (FDA) 的立場一致，並已導致該藥物退出歐洲市場。
  • 對現有數據的嚴格檢驗：這些監管措施促使全球重新評估支持使用該藥物的臨床數據，從而加強了對先前研究的檢驗，揭示了不一致的結果和陽性結果缺乏可重複性，削弱了人們對該藥物療效的信心。
  • 專注於複方製劑：隨著品牌藥的撤市，人們的注意力轉向了羥孕酮己酸酯的複方製劑。儘管這些製劑尚未獲得FDA核准，但一些醫療專業人員仍在繼續使用，這形成了一個利基市場，也表明儘管存在監管方面的擔憂，但該藥物的需求仍然存在。
  • 非專利藥替代的成長：在此之前，由於Makena非專利藥的推出，市場競爭加劇，價格下降，但當FDA撤銷了該品牌藥的核准時，也撤銷了這些非專利的核准，有效地阻止了這種成長趨勢。

羥孕酮己酸酯注射劑市場近期發展趨勢整體不利，主要全球市場紛紛撤離。這些事態發展正迫使早產預防治療模式發生根本性轉變，並促使醫學界探索並檢驗更有效、更安全的替代療法。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球羥孕酮己酸酯注射液市場（依產品類型分類）

  • 吸引力分析：依產品類型
  • 單劑量管瓶
  • 多劑量管瓶

5. 全球羥孕酮己酸酯注射液市場（依通路分類）

  • 吸引力分析：按分銷管道分類
  • 醫院藥房
  • 零售藥房
  • 網路藥房

6. 全球羥孕酮己酸酯注射液市場（依應用分類）

  • 吸引力分析：依目的
  • 預防早產
  • 荷爾蒙補充療法
  • 其他

第7章 區域分析

8. 北美羥孕酮己酸酯注射液市場

  • 北美羥孕酮己酸酯注射液市場（按類型分類）
  • 北美羥孕酮己酸酯注射液市場（按應用領域分類）
  • 美國羥孕酮己酸酯注射液市場
  • 墨西哥羥孕酮己酸酯注射液市場
  • 加拿大羥孕酮己酸酯注射液市場

9. 歐洲羥孕酮己酸酯注射液市場

  • 歐洲羥孕酮己酸酯注射液市場（按類型分類）
  • 歐洲羥孕酮己酸酯注射液市場按應用領域分類
  • 德國羥孕酮己酸酯注射液市場
  • 法國羥孕酮己酸酯注射液市場
  • 西班牙羥孕酮己酸酯注射液市場
  • 義大利羥孕酮己酸酯注射液市場
  • 英國羥孕酮己酸酯注射液市場

10. 亞太地區羥孕酮己酸酯注射液市場

  • 亞太地區羥孕酮己酸酯注射液市場（按類型分類）
  • 亞太地區羥孕酮己酸酯注射液市場（按應用分類）
  • 日本羥孕酮己酸酯注射液市場
  • 印度羥孕酮己酸酯注射液市場
  • 中國羥孕酮己酸酯注射液市場
  • 韓國羥孕酮己酸酯注射液市場
  • 印尼羥孕酮己酸酯注射液市場

11. 世界其他地區（ROW）羥孕酮己酸酯注射液市場

  • ROW羥孕酮己酸酯注射液市場按類型分類
  • 按應用領域分類的羥孕酮己酸酯注射液市場
  • 中東羥孕酮己酸酯注射液市場
  • 南美洲羥孕酮己酸酯注射液市場
  • 非洲羥孕酮己酸酯注射劑市場

第12章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
  • 市佔率分析

第13章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 全球羥孕酮己酸酯注射液市場新興趨勢
  • 戰略分析

第14章 價值鏈中主要企業的概況

  • 競爭分析
  • AMAG Pharmaceuticals
  • McGuff Pharmaceuticals
  • Aspen Oss
  • American Regent
  • Bayer
  • Teva Pharmaceutical Industries
  • Mylan
  • Pfizer
  • Sanofi
  • Merck & Co.

第15章附錄

The future of the global hydroxyprogesterone caproate injection market looks promising with opportunities in the preterm birth prevention and hormone replacement therapy markets. The global hydroxyprogesterone caproate injection market is expected to grow with a CAGR of 6.2% from 2025 to 2031. The major drivers for this market are the increasing number of preterm birth cases, the rising demand for maternal health therapies, and the growing focus on prenatal care solutions.

  • Lucintel forecasts that, within the product type category, multi-dose vial is expected to witness higher growth over the forecast period.
  • Within the application category, preterm birth prevention is expected to witness higher growth.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Hydroxyprogesterone Caproate Injection Market

The hydroxyprogesterone caproate injection market is currently experiencing a period of significant uncertainty and contraction due to a re-evaluation of its clinical efficacy. Emerging trends are not focused on growth but rather on a fundamental shift away from this drug, highlighting a search for alternative and more effective interventions for preterm birth prevention.

  • Shift to Alternative Progestogens: The most significant trend is the shift away from hydroxyprogesterone caproate and toward alternative progestogens, particularly natural progesterone. Healthcare providers are increasingly prescribing vaginal or oral progesterone as a substitute, backed by more recent clinical evidence of efficacy and a better safety profile, thereby transforming the market.
  • Increased Focus on Progesterone Research: The regulatory actions against hydroxyprogesterone caproate have fueled a trend toward increased research into progesterone's role in pregnancy. Scientists are now focusing on understanding the mechanisms of action and optimal delivery methods of progesterone to find a truly effective and safe treatment for preterm birth.
  • Growth in Personalized Medicine: An emerging trend is the move toward personalized medicine in preterm birth prevention. Instead of a one-size-fits-all approach, a growing focus on identifying individual patient risk factors, such as cervical length, is leading to more targeted and effective interventions that move beyond a reliance on a single drug.
  • Re-evaluation of Clinical Trial Data: A key trend is the re-evaluation of historical clinical trial data. The failure of a confirmatory trial to prove the efficacy of hydroxyprogesterone caproate has highlighted the need for more rigorous, well-designed studies in obstetrics. This is raising the bar for future drug approvals and the standards of medical evidence.
  • Focus on Non-Pharmacological Interventions: The challenges facing hydroxyprogesterone caproate are driving a trend toward a renewed focus on non-pharmacological interventions. This includes lifestyle changes, improved maternal nutrition, and integrated care models. This shift emphasizes a holistic approach to maternal health and well-being.

The emerging trends in the hydroxyprogesterone caproate market are not trends of growth, but rather of dissolution. The market is being reshaped by regulatory actions and scientific findings that have highlighted its inefficacy and potential risks, leading to a fundamental shift toward safer and more effective alternatives and a new era of research in maternal health.

Recent Developments in the Hydroxyprogesterone Caproate Injection Market

The hydroxyprogesterone caproate injection market has experienced profound recent developments, largely defined by regulatory actions that have challenged the drug's long-standing use. These developments have led to the withdrawal of the drug from key markets, compelling a re-evaluation of treatment strategies for preventing preterm birth.

  • FDA Withdrawal of Makena: A landmark development was the U.S. FDA's decision to withdraw the approval of Makena, the branded hydroxyprogesterone caproate injection, in 2023. This action followed a confirmatory trial that failed to show a clinical benefit. This development has effectively eliminated the drug from the U.S. market.
  • European EMA Suspension: In a parallel development, the European Medicines Agency (EMA) recommended the suspension of the drug's marketing authorizations across the EU. Citing a lack of efficacy in preventing preterm birth and an unconfirmed but possible risk of cancer in offspring, this action mirrors the FDA's stance and is leading to its withdrawal from European markets.
  • Heightened Scrutiny of Existing Data: These regulatory actions have prompted a global re-evaluation of the clinical data supporting the drug's use. This has created a heightened level of scrutiny on historical studies, revealing inconsistencies and a failure to replicate positive results, which has eroded confidence in the drug's effectiveness.
  • Focus on Compounded Alternatives: In response to the withdrawal of the branded product, a development has been the increased focus on compounded versions of hydroxyprogesterone caproate. While these formulations are not FDA-approved, some practitioners have continued to use them, creating a niche market and highlighting a continued demand for the drug despite regulatory findings.
  • Growth of Generic Alternatives: The market had previously seen a development with the introduction of generic versions of Makena, which increased competition and lowered prices. However, with the FDA's withdrawal of approval for the branded drug, these generic approvals were also rescinded, effectively halting this growth trajectory.

The recent developments in the hydroxyprogesterone caproate injection market have been overwhelmingly negative, centered on its withdrawal from major global markets. These developments are forcing a fundamental change in the treatment paradigm for preterm birth prevention, pushing the medical community to seek out and validate more effective and safer alternatives.

Strategic Growth Opportunities in the Hydroxyprogesterone Caproate Injection Market

Given the significant regulatory setbacks, strategic growth opportunities in the hydroxyprogesterone caproate injection market are limited and highly challenging. Any opportunities that exist are not in expansion but rather in a re-evaluation of its niche applications and a potential re-entry to the market with new, verifiable evidence.

  • Re-evaluation in Niche Indications: A strategic opportunity could involve a re-evaluation of hydroxyprogesterone caproate's use in highly specific, niche indications where it may still show some efficacy. This could involve small, targeted clinical trials to validate its use in specific patient subgroups or for other gynecological conditions beyond preterm birth prevention.
  • Development of New Formulations: A potential growth opportunity could be the development of a new formulation or delivery system with a better safety profile and proven efficacy. This would require a significant investment in R&D and a new clinical trial program to meet stringent regulatory requirements, offering a pathway for a product to re-enter the market.
  • Focus on Emerging Markets: While major markets are withdrawing the drug, a strategic opportunity might exist in emerging markets where regulatory standards and access to alternatives may differ. Companies could focus on gaining approvals in these regions, provided they can demonstrate a favorable risk-benefit profile to local authorities.
  • Partnerships for Re-research: Another opportunity lies in forming strategic partnerships with academic institutions and research organizations to conduct new, large-scale, well-designed clinical trials. This is crucial for gathering the robust evidence needed to either re-establish the drug's efficacy or definitively prove its lack thereof.
  • Market for Compounded Formulations: While highly controversial, a growth opportunity currently exists in the compounded pharmacy market. Companies could strategically focus on providing high-quality active pharmaceutical ingredients (APIs) to compounding pharmacies, catering to the remaining demand for this product in the absence of a branded version.

The strategic growth opportunities in the hydroxyprogesterone caproate market are not for business as usual. They are high-risk, high-investment endeavors focused on rebuilding a market that has been largely dismantled by regulatory bodies. Any future success would require a complete paradigm shift and the generation of new, compelling clinical evidence.

Hydroxyprogesterone Caproate Injection Market Driver and Challenges

The hydroxyprogesterone caproate injection market is characterized by a unique set of drivers and challenges. The market's previous growth was driven by a high demand for preterm birth prevention and initial clinical findings. However, its recent decline is overwhelmingly influenced by new, contradictory evidence and stringent regulatory actions.

The factors responsible for driving the hydroxyprogesterone caproate injection market include:

1. High Preterm Birth Rates: The primary historical driver was the high global incidence of preterm birth, a leading cause of infant morbidity and mortality. This created a significant and urgent medical need for an effective prophylactic treatment, which hydroxyprogesterone caproate was initially believed to be.

2. Initial Favorable Clinical Data: The market was initially driven by the positive results from a 2003 clinical trial (Meis Trial) that suggested the drug was effective in preventing recurrent preterm birth. This trial provided the foundation for the drug's initial accelerated approval and widespread adoption.

3. Orphan Drug Designation: The drug's orphan drug status in the U.S. provided significant market exclusivity and incentives for its development. This protected the branded product from immediate generic competition and drove investment, allowing it to become a major player in maternal health.

4. Perceived Lack of Alternatives: For a period, hydroxyprogesterone caproate was viewed as the only FDA-approved treatment for its specific indication, which was a strong market driver. The perceived lack of effective alternatives for high-risk women fueled its widespread use.

5. Physician Recommendation: The endorsement by major medical societies and organizations, based on the initial clinical data, was a significant driver. This helped solidify its position as a standard of care and encouraged obstetricians to prescribe the drug to eligible patients.

Challenges in the hydroxyprogesterone caproate injection market are:

1. Failure to Confirm Efficacy: The most significant challenge is the failure of a large, confirmatory clinical trial (PROLONG study) to prove the drug's efficacy. This finding directly contradicted the initial data, leading to a loss of confidence and the ultimate withdrawal of the product.

2. Regulatory Actions and Withdrawal: The U.S. FDA's and European EMA's decisions to withdraw or suspend the drug's marketing authorizations are insurmountable challenges. These regulatory actions are effectively eliminating the product from major global markets, making it difficult for it to be prescribed or sold.

3. Potential Safety Concerns: The unconfirmed but possible link to an increased risk of cancer in offspring exposed to the drug in utero is a major challenge. This safety concern, cited by the EMA, further undermines its benefit-risk profile and makes its use highly controversial.

The hydroxyprogesterone caproate market's trajectory has been a cautionary tale. While once driven by a clear medical need and promising initial data, it has been decimated by the failure to confirm its efficacy and the subsequent regulatory actions. The challenges are now far greater than the initial drivers, making the market's future highly uncertain.

List of Hydroxyprogesterone Caproate Injection Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hydroxyprogesterone caproate injection companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hydroxyprogesterone caproate injection companies profiled in this report include-

  • AMAG Pharmaceuticals
  • McGuff Pharmaceuticals
  • Aspen Oss
  • American Regent
  • Bayer
  • Teva Pharmaceutical Industries
  • Mylan
  • Pfizer
  • Sanofi
  • Merck & Co.

Hydroxyprogesterone Caproate Injection Market by Segment

The study includes a forecast for the global hydroxyprogesterone caproate injection market by product type, distribution channel, application, and region.

Hydroxyprogesterone Caproate Injection Market by Product Type [Value from 2019 to 2031]:

  • Single-Dose Vials
  • Multi-Dose Vials

Hydroxyprogesterone Caproate Injection Market by Distribution Channel [Value from 2019 to 2031]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hydroxyprogesterone Caproate Injection Market by Application [Value from 2019 to 2031]:

  • Preterm Birth Prevention
  • Hormone Replacement Therapy
  • Others

Country Wise Outlook for the Hydroxyprogesterone Caproate Injection Market

The hydroxyprogesterone caproate injection market is facing significant global challenges and a period of re-evaluation. Recent developments are primarily centered around regulatory actions and a re-assessment of the drug's efficacy and safety profile. These shifts are challenging its long-standing position as a primary therapy for preventing preterm birth.

  • United States: The U.S. market has undergone a dramatic change. Following a review that failed to confirm its clinical benefit, the FDA withdrew its approval for the branded drug Makena and its generics in 2023. This has led to the complete removal of the product from the market, fundamentally reshaping the landscape for preterm birth prevention.
  • China: The market in China is at an early stage, with limited data available on the use of hydroxyprogesterone caproate injections. While preterm birth prevention is a medical priority, the market is not as developed as in other regions. There is a need for further research and clinical data to establish the drug's role in the country's healthcare system.
  • Germany: In Germany, and across the EU, the European Medicines Agency (EMA) has recommended the suspension of marketing authorizations for hydroxyprogesterone caproate-containing medicines. This decision, based on a lack of efficacy and a possible but unconfirmed cancer risk in offspring, is prompting a withdrawal of the drug from the market.
  • India: The Indian market is currently small and not a primary focus for this treatment. However, as preterm birth rates are a significant public health issue, there is a potential for future growth. The market is driven by increasing awareness and improving healthcare infrastructure, but the drug's recent regulatory setbacks may impact its future in India.
  • Japan: Japan's market is characterized by a cautious approach to new and existing drugs. The use of hydroxyprogesterone caproate injections is limited. The drug's recent regulatory setbacks in the U.S. and Europe are likely to influence Japan's regulatory bodies and medical community, leading to a potential re-evaluation of its use.

Features of the Global Hydroxyprogesterone Caproate Injection Market

  • Market Size Estimates: Hydroxyprogesterone caproate injection market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Hydroxyprogesterone caproate injection market size by product type, distribution channel, application, and region in terms of value ($B).
  • Regional Analysis: Hydroxyprogesterone caproate injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different product types, distribution channels, applications, and regions for the hydroxyprogesterone caproate injection market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hydroxyprogesterone caproate injection market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hydroxyprogesterone caproate injection market by product type (single-dose vials and multi-dose vials), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (preterm birth prevention, hormone replacement therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Hydroxyprogesterone Caproate Injection Market by Product Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Product Type
  • 4.3 Single-Dose Vials: Trends and Forecast (2019-2031)
  • 4.4 Multi-Dose Vials: Trends and Forecast (2019-2031)

5. Global Hydroxyprogesterone Caproate Injection Market by Distribution Channel

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Distribution Channel
  • 5.3 Hospital Pharmacies: Trends and Forecast (2019-2031)
  • 5.4 Retail Pharmacies: Trends and Forecast (2019-2031)
  • 5.5 Online Pharmacies: Trends and Forecast (2019-2031)

6. Global Hydroxyprogesterone Caproate Injection Market by Application

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Application
  • 6.3 Preterm Birth Prevention: Trends and Forecast (2019-2031)
  • 6.4 Hormone Replacement Therapy: Trends and Forecast (2019-2031)
  • 6.5 Others: Trends and Forecast (2019-2031)

7. Regional Analysis

  • 7.1 Overview
  • 7.2 Global Hydroxyprogesterone Caproate Injection Market by Region

8. North American Hydroxyprogesterone Caproate Injection Market

  • 8.1 Overview
  • 8.2 North American Hydroxyprogesterone Caproate Injection Market by Product Type
  • 8.3 North American Hydroxyprogesterone Caproate Injection Market by Application
  • 8.4 United States Hydroxyprogesterone Caproate Injection Market
  • 8.5 Mexican Hydroxyprogesterone Caproate Injection Market
  • 8.6 Canadian Hydroxyprogesterone Caproate Injection Market

9. European Hydroxyprogesterone Caproate Injection Market

  • 9.1 Overview
  • 9.2 European Hydroxyprogesterone Caproate Injection Market by Product Type
  • 9.3 European Hydroxyprogesterone Caproate Injection Market by Application
  • 9.4 German Hydroxyprogesterone Caproate Injection Market
  • 9.5 French Hydroxyprogesterone Caproate Injection Market
  • 9.6 Spanish Hydroxyprogesterone Caproate Injection Market
  • 9.7 Italian Hydroxyprogesterone Caproate Injection Market
  • 9.8 United Kingdom Hydroxyprogesterone Caproate Injection Market

10. APAC Hydroxyprogesterone Caproate Injection Market

  • 10.1 Overview
  • 10.2 APAC Hydroxyprogesterone Caproate Injection Market by Product Type
  • 10.3 APAC Hydroxyprogesterone Caproate Injection Market by Application
  • 10.4 Japanese Hydroxyprogesterone Caproate Injection Market
  • 10.5 Indian Hydroxyprogesterone Caproate Injection Market
  • 10.6 Chinese Hydroxyprogesterone Caproate Injection Market
  • 10.7 South Korean Hydroxyprogesterone Caproate Injection Market
  • 10.8 Indonesian Hydroxyprogesterone Caproate Injection Market

11. ROW Hydroxyprogesterone Caproate Injection Market

  • 11.1 Overview
  • 11.2 ROW Hydroxyprogesterone Caproate Injection Market by Product Type
  • 11.3 ROW Hydroxyprogesterone Caproate Injection Market by Application
  • 11.4 Middle Eastern Hydroxyprogesterone Caproate Injection Market
  • 11.5 South American Hydroxyprogesterone Caproate Injection Market
  • 11.6 African Hydroxyprogesterone Caproate Injection Market

12. Competitor Analysis

  • 12.1 Product Portfolio Analysis
  • 12.2 Operational Integration
  • 12.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

  • 13.1 Value Chain Analysis
  • 13.2 Growth Opportunity Analysis
    • 13.2.1 Growth Opportunities by Product Type
    • 13.2.2 Growth Opportunities by Distribution Channel
    • 13.2.3 Growth Opportunities by Application
  • 13.3 Emerging Trends in the Global Hydroxyprogesterone Caproate Injection Market
  • 13.4 Strategic Analysis
    • 13.4.1 New Product Development
    • 13.4.2 Certification and Licensing
    • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

  • 14.1 Competitive Analysis
  • 14.2 AMAG Pharmaceuticals
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.3 McGuff Pharmaceuticals
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.4 Aspen Oss
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.5 American Regent
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.6 Bayer
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.7 Teva Pharmaceutical Industries
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.8 Mylan
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.9 Pfizer
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.10 Sanofi
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.11 Merck & Co.
    • Company Overview
    • Hydroxyprogesterone Caproate Injection Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

15. Appendix

  • 15.1 List of Figures
  • 15.2 List of Tables
  • 15.3 Research Methodology
  • 15.4 Disclaimer
  • 15.5 Copyright
  • 15.6 Abbreviations and Technical Units
  • 15.7 About Us
  • 15.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Hydroxyprogesterone Caproate Injection Market
  • Figure 2.1: Usage of Hydroxyprogesterone Caproate Injection Market
  • Figure 2.2: Classification of the Global Hydroxyprogesterone Caproate Injection Market
  • Figure 2.3: Supply Chain of the Global Hydroxyprogesterone Caproate Injection Market
  • Figure 3.1: Driver and Challenges of the Hydroxyprogesterone Caproate Injection Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Hydroxyprogesterone Caproate Injection Market by Product Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Hydroxyprogesterone Caproate Injection Market ($B) by Product Type
  • Figure 4.3: Forecast for the Global Hydroxyprogesterone Caproate Injection Market ($B) by Product Type
  • Figure 4.4: Trends and Forecast for Single-Dose Vials in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Multi-Dose Vials in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 5.1: Global Hydroxyprogesterone Caproate Injection Market by Distribution Channel in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Hydroxyprogesterone Caproate Injection Market ($B) by Distribution Channel
  • Figure 5.3: Forecast for the Global Hydroxyprogesterone Caproate Injection Market ($B) by Distribution Channel
  • Figure 5.4: Trends and Forecast for Hospital Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Retail Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Online Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 6.1: Global Hydroxyprogesterone Caproate Injection Market by Application in 2019, 2024, and 2031
  • Figure 6.2: Trends of the Global Hydroxyprogesterone Caproate Injection Market ($B) by Application
  • Figure 6.3: Forecast for the Global Hydroxyprogesterone Caproate Injection Market ($B) by Application
  • Figure 6.4: Trends and Forecast for Preterm Birth Prevention in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 6.5: Trends and Forecast for Hormone Replacement Therapy in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 6.6: Trends and Forecast for Others in the Global Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Figure 7.1: Trends of the Global Hydroxyprogesterone Caproate Injection Market ($B) by Region (2019-2024)
  • Figure 7.2: Forecast for the Global Hydroxyprogesterone Caproate Injection Market ($B) by Region (2025-2031)
  • Figure 8.1: North American Hydroxyprogesterone Caproate Injection Market by Product Type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the North American Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2019-2024)
  • Figure 8.3: Forecast for the North American Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2025-2031)
  • Figure 8.4: North American Hydroxyprogesterone Caproate Injection Market by Application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the North American Hydroxyprogesterone Caproate Injection Market ($B) by Application (2019-2024)
  • Figure 8.6: Forecast for the North American Hydroxyprogesterone Caproate Injection Market ($B) by Application (2025-2031)
  • Figure 8.7: Trends and Forecast for the United States Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the Mexican Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Canadian Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 9.1: European Hydroxyprogesterone Caproate Injection Market by Product Type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the European Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2019-2024)
  • Figure 9.3: Forecast for the European Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2025-2031)
  • Figure 9.4: European Hydroxyprogesterone Caproate Injection Market by Application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the European Hydroxyprogesterone Caproate Injection Market ($B) by Application (2019-2024)
  • Figure 9.6: Forecast for the European Hydroxyprogesterone Caproate Injection Market ($B) by Application (2025-2031)
  • Figure 9.7: Trends and Forecast for the German Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the French Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Spanish Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Italian Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the United Kingdom Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 10.1: APAC Hydroxyprogesterone Caproate Injection Market by Product Type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the APAC Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2019-2024)
  • Figure 10.3: Forecast for the APAC Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2025-2031)
  • Figure 10.4: APAC Hydroxyprogesterone Caproate Injection Market by Application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the APAC Hydroxyprogesterone Caproate Injection Market ($B) by Application (2019-2024)
  • Figure 10.6: Forecast for the APAC Hydroxyprogesterone Caproate Injection Market ($B) by Application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Japanese Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the Indian Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the Chinese Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the South Korean Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 10.11: Trends and Forecast for the Indonesian Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 11.1: ROW Hydroxyprogesterone Caproate Injection Market by Product Type in 2019, 2024, and 2031
  • Figure 11.2: Trends of the ROW Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2019-2024)
  • Figure 11.3: Forecast for the ROW Hydroxyprogesterone Caproate Injection Market ($B) by Product Type (2025-2031)
  • Figure 11.4: ROW Hydroxyprogesterone Caproate Injection Market by Application in 2019, 2024, and 2031
  • Figure 11.5: Trends of the ROW Hydroxyprogesterone Caproate Injection Market ($B) by Application (2019-2024)
  • Figure 11.6: Forecast for the ROW Hydroxyprogesterone Caproate Injection Market ($B) by Application (2025-2031)
  • Figure 11.7: Trends and Forecast for the Middle Eastern Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 11.8: Trends and Forecast for the South American Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 11.9: Trends and Forecast for the African Hydroxyprogesterone Caproate Injection Market ($B) (2019-2031)
  • Figure 12.1: Porter's Five Forces Analysis of the Global Hydroxyprogesterone Caproate Injection Market
  • Figure 12.2: Market Share (%) of Top Players in the Global Hydroxyprogesterone Caproate Injection Market (2024)
  • Figure 13.1: Growth Opportunities for the Global Hydroxyprogesterone Caproate Injection Market by Product Type
  • Figure 13.2: Growth Opportunities for the Global Hydroxyprogesterone Caproate Injection Market by Distribution Channel
  • Figure 13.3: Growth Opportunities for the Global Hydroxyprogesterone Caproate Injection Market by Application
  • Figure 13.4: Growth Opportunities for the Global Hydroxyprogesterone Caproate Injection Market by Region
  • Figure 13.5: Emerging Trends in the Global Hydroxyprogesterone Caproate Injection Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Hydroxyprogesterone Caproate Injection Market by Product Type, Distribution Channel, and Application
  • Table 1.2: Attractiveness Analysis for the Hydroxyprogesterone Caproate Injection Market by Region
  • Table 1.3: Global Hydroxyprogesterone Caproate Injection Market Parameters and Attributes
  • Table 3.1: Trends of the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 3.2: Forecast for the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Hydroxyprogesterone Caproate Injection Market by Product Type
  • Table 4.2: Market Size and CAGR of Various Product Type in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Product Type in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 4.4: Trends of Single-Dose Vials in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 4.5: Forecast for Single-Dose Vials in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 4.6: Trends of Multi-Dose Vials in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 4.7: Forecast for Multi-Dose Vials in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Hydroxyprogesterone Caproate Injection Market by Distribution Channel
  • Table 5.2: Market Size and CAGR of Various Distribution Channel in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Distribution Channel in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 5.4: Trends of Hospital Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 5.5: Forecast for Hospital Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 5.6: Trends of Retail Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 5.7: Forecast for Retail Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 5.8: Trends of Online Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 5.9: Forecast for Online Pharmacies in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 6.1: Attractiveness Analysis for the Global Hydroxyprogesterone Caproate Injection Market by Application
  • Table 6.2: Market Size and CAGR of Various Application in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 6.3: Market Size and CAGR of Various Application in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 6.4: Trends of Preterm Birth Prevention in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 6.5: Forecast for Preterm Birth Prevention in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 6.6: Trends of Hormone Replacement Therapy in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 6.7: Forecast for Hormone Replacement Therapy in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 6.8: Trends of Others in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 6.9: Forecast for Others in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 7.1: Market Size and CAGR of Various Regions in the Global Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 7.2: Market Size and CAGR of Various Regions in the Global Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 8.1: Trends of the North American Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 8.2: Forecast for the North American Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Product Type in the North American Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Product Type in the North American Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the North American Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the North American Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 8.7: Trends and Forecast for the United States Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 8.8: Trends and Forecast for the Mexican Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Canadian Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 9.1: Trends of the European Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 9.2: Forecast for the European Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Product Type in the European Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Product Type in the European Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the European Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the European Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 9.7: Trends and Forecast for the German Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 9.8: Trends and Forecast for the French Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Spanish Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 9.10: Trends and Forecast for the Italian Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 9.11: Trends and Forecast for the United Kingdom Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 10.1: Trends of the APAC Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 10.2: Forecast for the APAC Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Product Type in the APAC Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Product Type in the APAC Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the APAC Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the APAC Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Japanese Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 10.8: Trends and Forecast for the Indian Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 10.9: Trends and Forecast for the Chinese Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 10.10: Trends and Forecast for the South Korean Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 10.11: Trends and Forecast for the Indonesian Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 11.1: Trends of the ROW Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 11.2: Forecast for the ROW Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 11.3: Market Size and CAGR of Various Product Type in the ROW Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 11.4: Market Size and CAGR of Various Product Type in the ROW Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 11.5: Market Size and CAGR of Various Application in the ROW Hydroxyprogesterone Caproate Injection Market (2019-2024)
  • Table 11.6: Market Size and CAGR of Various Application in the ROW Hydroxyprogesterone Caproate Injection Market (2025-2031)
  • Table 11.7: Trends and Forecast for the Middle Eastern Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 11.8: Trends and Forecast for the South American Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 11.9: Trends and Forecast for the African Hydroxyprogesterone Caproate Injection Market (2019-2031)
  • Table 12.1: Product Mapping of Hydroxyprogesterone Caproate Injection Suppliers Based on Segments
  • Table 12.2: Operational Integration of Hydroxyprogesterone Caproate Injection Manufacturers
  • Table 12.3: Rankings of Suppliers Based on Hydroxyprogesterone Caproate Injection Revenue
  • Table 13.1: New Product Launches by Major Hydroxyprogesterone Caproate Injection Producers (2019-2024)
  • Table 13.2: Certification Acquired by Major Competitor in the Global Hydroxyprogesterone Caproate Injection Market